<DOC>
	<DOCNO>NCT00003539</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining chemotherapy monoclonal antibody therapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness paclitaxel plus monoclonal antibody therapy treat woman recurrent metastatic breast cancer .</brief_summary>
	<brief_title>Paclitaxel Plus Monoclonal Antibody Therapy Treating Women With Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine therapeutic efficacy paclitaxel combination monoclonal antibody HER2 ( Herceptin ) woman recurrent metastatic breast cancer . II . Evaluate safety combination regimen patient . OUTLINE : Patients stratify tumor expression HER2 ( overexpression v normal ) . Patients receive load dose monoclonal antibody HER2 ( Herceptin ) intravenously 90 minute day 0 . Paclitaxel administer intravenously 1 hour day 1 . Starting day 7 , patient receive paclitaxel infusion 1 hour every 7 day . Monoclonal antibody HER2 administer intravenously 30 minute immediately follow paclitaxel every 7 day . Treatment continue absence disease progression unacceptable toxicity . Patients follow death . PROJECTED ACCRUAL : This study accrue 50 patient approximately 6 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent metastatic breast cancer Bidimensionally measurable disease No bone scan abnormality alone Lytic lesion allow conjunction bone scan abnormalities No pure blastic bone metastases No pleural peritoneal effusion No previously irradiate lesion Resected disease allow No brain metastasis leptomeningeal disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Granulocyte count least 1500/mm3 Hemoglobin least 8.0 g/dL Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL Renal : Creatinine le 2.0 mg/dL Calcium great 11.0 mg/dL Cardiovascular : No history arrhythmias No history significant cardiac diseases No New York Heart Association class III IV cardiac function Left ventricular ejection fraction least 50 % Pulmonary : No symptomatic lymphangitic pulmonary metastases Other : Not pregnant Negative pregnancy test No history malignancy except : Carcinoma situ cervix Curatively treat nonmelanoma skin cancer No severe infection No severe malnutrition No serious medical illness No history grade 34 peripheral neuropathy PRIOR CONCURRENT THERAPY : Biologic therapy : No prior monoclonal antibody therapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No 3 prior chemotherapy regimen adjuvant/neoadjuvant therapy disease At least 1 year since prior paclitaxel docetaxel Prior anthracycline ( doxorubicin epirubicin ) mitoxantronebased regimen allow adjuvant therapy advance disease No concurrent chemotherapy Endocrine therapy : At least 3 week since prior exogenous hormonal therapy stage IV disease and/or adjuvant therapy Radiotherapy : No radiotherapy great 50 % marrow At least 4 week since prior radiotherapy recover No concurrent radiotherepy measurable lesion Surgery : At least 23 week since prior surgery recover No concurrent surgery measurable lesion Other : No concurrent nonprotocol treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>